3 registrations that name kisspeptin-10 as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 3 registrations
Status
Phase
3US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 3 registrations
RecruitingNCT07224490
Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease
Phase 1
Stephanie B. Seminara, MD
About 40 people
Started Mar 10, 2026
In plain words A Phase 1 study of kisspeptin-10 in people 18 to 60, run by Stephanie B. Seminara, MD. It plans to enroll about 40 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 60. Conditions: Reproductive Disorder; Neurodegeneration; SARS-CoV 2; Long COVID.
Female (ages 18-45 years) or Male (ages 18-60 years)
No current or recent use of a medication (including hormonal replacement) that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its…
For women, negative serum hCG pregnancy test
For cases, diagnosis of post-covid-19 syndrome
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Kisspeptin 112-121
Registered summary
The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin.
Where, as registered
1 US site in 1 state.
RecruitingNCT05896293
Kisspeptin Administration Subcutaneously to Patients With IHH
Phase 2
Stephanie B. Seminara, MD
About 36 people
Started Feb 3, 2023
In plain words A Phase 2 study of kisspeptin-10 in people 18 and older, run by Stephanie B. Seminara, MD. It plans to enroll about 36 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Hypogonadotropic Hypogonadism.
Congenital IHH
Confirmed diagnosis by medical provider supported by low sex steroids in the setting of low or inappropriately normal gonadotropins
Normal blood pressure (systolic BP < 140 mm Hg, diastolic < 90 mm Hg)
No current or recent use of a medication that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and method of administration
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
kisspeptin 112-121; leuprolide acetate
Registered summary
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in men and women with idiopathic hypogonadotropic hypogonadism (IHH). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered SC for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (every 10 minutes for up to 70 minutes) will be performed to assess the physiologic response to kisspeptin over time. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07224438
Kisspeptin Administration Subcutaneously to Patients With Hypothalamic Amenorrhea
Phase 2
Stephanie B. Seminara, MD
About 20 people
Started Dec 9, 2025
In plain words A Phase 2 study of kisspeptin-10 in female participants 18 to 45, run by Stephanie B. Seminara, MD. It plans to enroll about 20 people at 1 US site.
Normal blood pressure (systolic BP < 140 mm Hg, diastolic < 90 mm Hg)
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
kisspeptin 112-121
Registered summary
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.